Abstract: For the therapy of neurological complications in AIDS sufferers, the use of pharmaceutical compositions containing as an active principle at least one compound selected from the group consisting of S-adenosyl-L-methionine salt, 5-methyl-tetrahydro-folic acid, 5-formyltetrahydro-folic acid, when the active principle consists of S-adenosyl-L-methionine and of a derivative of tetrahydro folic acid, the weight ratio between the S-adenosyl-L-methionine salt and 5-methyltetrahydrofolic acid or 5-formyl-tetrahydrofolic acid is comprised between 10/1 and 4/1, in pharmaceutical form, suitable for oral or parenteral administration.

Abstract: This invention relates to pharmaceutical compositions containing 5'-deoxy-5'-methylthioadenosine, S-adenosyl-methionine and their pharmaceutically acceptable salts able to reduce scalp seborrhea and its related furfuraceous desquamation and pruritus.

Abstract: The present invention refers to the use of 5-methyltetrahydrofolic acid, of 5-formyltetrahydrofolic acid and of their pharmaceutically acceptable salts for the preparation of controlled release pharmaceutical compositions suitable for the use in the therapy of depressive disturbances, in particular major depression, dysthymia or depressive neurosis and not otherwise specified depressive disturbances, independently from folate plasmatic levels, and to the pharmaceutical composition thus prepared.

Abstract: A method for preparing d,1-5-methyltetrahydrofolic acid and the salts thereof of the formula: ##STR1## wherein X is hydrogen, an alkaline metal or alkaline earth metal; by reduction of folic acid with sodium borohydride followed by the methylation of the tetrahydrofolic acid thus obtained with aqueous solutions of formaldehye and sodium borohydride in an inert atmosphere.

Abstract: Therapeutic composition comprising S-adenosyl-methionine useful in the treatment of pancreatitis and as synergistic agent of cyclosporin in the prevention of the graft rejection in pancreas transplant.

Abstract: This invention relates to new stable sulpho-adenosyl-L-methionine (SAMe) salts and the relative production process.Said salts have the following general formula:SAMe.nR(O).sub.m (SO.sub.3 H).sub.p (I)where m can be zero or 1; n is 1.5 when p is 2, and is 3 when p is 1; R is chosen from the group consisting of alkyl, phenylalkyl and carboxyalkyl, in which the linear or branched alkyl chain contains from 8 to 18 carbon atoms.In particular, the salts according to the present invention are SAMe salts of sulphonic acids, or of sulphuric acid esters, or of dioctylsulphosuccinic acid, which fall within formula (I).The process for producing said salts consists of: a) enriching the starting yeast with SAMe; b) lysing the cells and recovering an aqueous solution rich in SAMe (cell lysate); c) purifying the lysate by ultrafiltration; d) precipitating the SAMe by treatment with one of the aforesaid acids or esters; e) separating the precipitated product, washing it and drying it under vacuum.

Abstract: A method for preparing d,1-5-methyltetrahydrofolic acid and the salts thereof of the formula: ##STR1## wherein X is hydrogen, an alkaline metal or alkaline earth metal; by reduction of folic acid with sodium borohydride followed by the methylation of the tetrahydrofolic acid thus obtained with aqueous solutions of formaldehyde and sodium borohydride in an inert atmosphere.

Abstract: The invention discloses injectable therapeutic compositions containing stable S-adenosyl-L-methionine (SAMe) salts as an active ingredient. Injectable therapeutic compositions which permit large doses of SAMe to be administered by injection, at physiological pH having excellent tolerability has been achieved by administering SAMe salts in an aqueous solution which is adjusted to a pH of between 5 and 8.5 containing an amino acid and an alkaline base in critical proportions.

Abstract: The present invention relates to new stable sulpho-adenosyl-L-methionine (SAMe) salts particulary suitable for parenteral use, their production process, and pharmaceutical compositions containing them as active principles.Said salts correspond to the general formula:SAMe.n(CH.sub.2).sub.m (SO.sub.3 H).sub.2 (I)where n can vary from 1 to 2 and m can vary from 3 to 12.The process for producing said salts consists of the following stages: a) enriching the starting yeast with SAMe; b) lysing the cells and recovering a solution rich in SAMe (cell lysate); c) prepurifying the cell lysate by ultrafiltration; d) passing the prepurified lysate through a column of weak acid ion exchange resin and eluting with the required disulphonic acid; e) passing the eluate of said column through a colum of absorption resin and washing with the required disulphonic acid; f) concentrating the eluate of the later column by reverse osmosis; g) drying the concentrated solution.

Abstract: This invention relates to pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutical acceptable salts in controlled-release form which are active in the therapy of organic mental disturbances and in particular in the treatment of senile and presenile primary degenerative dementia of Alzheimer type and multiinfarctual dementia.

Abstract: Pteridines of general formula (I): ##STR1## in which Y and Z, which can be identical or different, are hydrogen, OH or NH.sub.2, and X.sub.1 and X.sub.2, which can be identical or different, are hydrogen, OH, C.sub.1 -C.sub.4 alkyl, phenyl, hydroxymethyl or carboxyl, for the preparation of pharmaceutical compositions for treating cognitive pathologies characterized by memory and vigilance disturbances, such as senile dementia of Alzheimer type, multiinfarctual dementia, metabolic encephalopathies, Korsakoff's syndrome, and the consequences of the abuse of certain therapies such as anxiolytic and neuroleptic.

Abstract: The present invention relates to new stable sulpho-adenosyl-L-methionine (SAMe) salts particularly suitable for parenteral use, their production process, and pharmaceutical compositions containing them as active principles.Said salts correspond to the general formula:SAMe.n(CH.sub.2).sub.m (SO.sub.3 H).sub.2 (I)where n can vary from 1 to 2 and m can vary from 3 to 12.The process for producing said salts consists of the following stages: (a) enriching the starting yeast with SAMe; (b) lysing the cells and recovering a solution rich is SAMe (cell lysate); (c) prepurifying the cell lysate by ultrafiltration; (d) passing the prepurified lysate through a column of weak acid ion exchange resin and eluting with the required disulphonic acid; (e) passing the eluate of said column through a column of absorption resin and washing with the required disulphonic acid; (f) concentrating the eluate of the latter column by reverse osmosis; (g) drying the concentrated solution.

Abstract: A process is described for the large-scale industrial production of any stable SAMe salt at very high purity and with a yield of about 90% or more.The new process is characterized by the following basic operations: (a) production of yeast containing 12-20 g/kg of SAMe, (b) cell lysis and recovery of the SAMe-rich lysate, (c) ultrafiltration of the lysate, (d) passage through weak acid ion exchange resin, (e) passage through absorption resin, (f) concentration by reverse osmosis, (g) spray-drying the concentrated aqueous solution of SAMe salt.

Abstract: New S-adenosylmethionine (SAM) salts of formula ##STR1## have been prepared in which R, R.sub.1, R.sub.2, m, n and A are as defined in the text.The methods of preparing the new products starting from SAM salts are described.The new products are stable and highly bioavailable, particularly when administered orally.

Abstract: S-adenosylmethionine salts have been prepared which are stable even at elevated temperatures for practically indefinite time periods, and which correspond to the formula ##STR1## in which X is the acid equivalent of a strong mineral acid of pK less than 2.5, and n is 4, 5 or 6.The new salts are practically free from toxicity, and find application in numerous fields of human therapy.

Abstract: New S-adenosylmethionine salts have been prepared which are stable indefinitely with time, even at elevated temperatures.The new salts correspond to the formula: ##STR1## in which X is the equivalent of an organic sulphonic acid of pK less than 2.5,and possess therapeutic activity in numerous fields of human therapy.